Articles
January 31, 2023
Alnylam Named to Bloomberg's Gender-Equality Index for 3rd Year in a Row
Alnylam has been named to Bloomberg's Gender Equality Index (GEI) for the 3rd year in a row.
Read More ›
December 8, 2022
Alnylam Named One of America's Most Responsible Companies by Newsweek
Alnylam has been named one of America's Most Responsible Companies for 2023 by Newsweek and research firm Statista
Read More ›
November 30, 2022
Alnylam Named #1 Largest Employer in MA for 2nd Year in a Row by The Boston Globe
Alnylam is a Boston Globe Top Place to Work for the 8th consecutive year and the #1 ranked company on the "Largest Employers" list for the second year in a row
Read More ›
October 26, 2022
Alnylam Named #2 <em>Science Magazine</em> Top Biopharma Employer
Alnylam has been named the #2 Science Magazine Top Biopharma Employer for 2022, which marks our 4th year on the list.
Read More ›
October 24, 2022
“Be the Link!” Learn from patients on World Amyloidosis Day
No one knows this better than Jean-Christophe Fidalgo, President of the Amyloidosis Alliance, who has been living with hATTR amyloidosis for more than 20 years.
Read More ›
September 27, 2022
Alnylam Named a Best Workplace for Women by Fortune Magazine
Alnylam has been named a Fortune Best Workplace for Women for 2022
Read More ›
August 2, 2022
Alnylam Named #1 Best Workplace for Innovators by Fast Company
Alnylam has been named the #1 Best Workplace for Innovators by Fast Company for 2022.
Read More ›
July 13, 2022
Partnering with Nucleate to Support Young Biotech Entrepreneurs
Alnylam is partnering with Nucleate to remove barriers for young biotech entrepreneurs...
Read More ›
June 20, 2022
Challenging Ourselves to Help Refugees: Supporting Refugees to Become Work-Ready
Alnylam has announced a three-year corporate partnership with Refugee Action, a United Kingdom (UK)-based charity dedicated to helping refugees...
Read More ›
May 13, 2022
Hypertension: Charting A New Course to Address a Public Health Challenge
Hypertension (high blood pressure) has seen limited medical innovation in recent history and remains a serious public health issue...
Read More ›
